Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer

被引:10
作者
Vidal, Gloria Cordeiro [1 ]
Babin, Guillaume [1 ]
Querleu, Denis [1 ]
Guyon, Frederic [1 ]
机构
[1] Ctr Reg Lutte Canc, Inst Bergonie, 229 Cour, Bordeaux, France
关键词
Cytoreduction; Debulking; Ovarian cancer; Plasma; Diaphragmatic surgery;
D O I
10.1016/j.ygyno.2016.10.030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[Figure presented] Objective: Electrically neutral argon plasma (PlasmaJet™) technology is a surgical option that helps to get an aggressive cytoreduction in selected patients with ovarian cancer because it can be directly applied by the surgeon to treat the tissue surface [1,2]. Upper abdominal surgical procedures are an important part of the surgery in these patients [3], there is a 22% complications rate when they are performed [4]. We present a surgical approach to ovarian cancer debulking using PlasmaJet™. Methods: Case history and operative technique: 51 women supported for ovarian cancer Stage IIIC-IV were operated with systematic use of the PlasmaJet device at the Regional Institute Bergonié Cancer Center of Bordeaux, France between June 2012 and June 2014. 41.2% (n = 21) patients underwent a Primary Debulking Surgery (PDS) and 58.8% (n = 30) underwent an Interval Debulking Surgery. 78.4% (n = 40) of the 51 patients studied had a complete cytoreduction. We present the case of a woman diagnosed with a mucinous ovarian carcinoma FIGO stage IVA, who underwent a PDS. Complete cytoreduction to no macroscopic disease was achieved, this included diaphragmatic and abdominal peritoneal stripping. Results: No post-operative complications were found in this case. 15.7% (n = 8) of patients undergoing diaphragmatic stripping with the PlasmaJet required a pleural drain. It is a safe structured procedure, which could be performed to achieve optimal surgical results for patients with ovarian cancer. Conclusions: PlasmaJet™ helps the surgeon to perform a peritoneal stripping of the upper abdominal areas and appears to enable the surgeon to remove more disease without increased morbidity, pushing the cytoreduction/morbidity tradeoff. © 2016 Elsevier Inc.
引用
收藏
页码:223 / 224
页数:2
相关论文
共 50 条
  • [31] Experience with PlasmaJet™ in debulking surgery in 87 patients with advanced-stage ovarian cancer
    Volcke, Alexander
    Van Nieuwenhuysen, Els
    Han, Sileny
    Salihi, Rawand
    Van Gorp, Toon
    Vergote, Ignace
    JOURNAL OF SURGICAL ONCOLOGY, 2021, 123 (04) : 1109 - 1114
  • [32] Meigs to modern times: The evolution of debulking surgery in advanced ovarian cancer
    Schorge, John O.
    Bregar, Amy J.
    Durfee, John
    Berkowitz, Ross S.
    GYNECOLOGIC ONCOLOGY, 2018, 149 (03) : 447 - 454
  • [33] Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma
    Shelly M. Seward
    Ira Winer
    Cancer and Metastasis Reviews, 2015, 34 : 5 - 10
  • [34] Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer
    Luger, Anna K.
    Steinkohl, Fabian
    Aigner, Friedrich
    Jaschke, Werner
    Marth, Christian
    Zeimet, Alain G.
    Reimer, Daniel
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2020, 99 (08) : 1092 - 1099
  • [35] Nomogram to predict feasibility of minimally invasive interval debulking surgery in advanced ovarian cancer
    Conte, Carmine
    Rosati, Andrea
    Marchetti, Claudia
    Iacobelli, Valentina
    Quagliozzi, Lorena
    Gallucci, Valeria
    Alletti, Salvatore Gueli
    Scambia, Giovanni
    Fagotti, Anna
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (04) : 532 - 539
  • [36] Primary Versus Interval Debulking Surgery in Advanced Ovarian Cancer Results From a Systematic Single-Center Analysis
    Sehouli, Jalid
    Savvatis, Konstantinos
    Braicu, Elena-Ioana
    Schmidt, Sven-Christian
    Lichtenegger, Werner
    Fotopoulou, Christina
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (08) : 1331 - 1340
  • [37] Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma
    Seward, Shelly M.
    Winer, Ira
    CANCER AND METASTASIS REVIEWS, 2015, 34 (01) : 5 - 10
  • [38] Comparison of platinum-based neoadjuvant chemotherapy and primary debulking surgery in patients with advanced ovarian cancer
    Sayyah-Melli M.
    Zonoozi G.K.
    Hashemzadeh S.
    Esfahani A.
    Ouladehsahebmadarek E.
    Shobeiry M.J.
    Garabaghi P.M.
    Ramin A.
    The Journal of Obstetrics and Gynecology of India, 2013, 63 (6) : 405 - 409
  • [39] Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer
    Tseng, Jill H.
    Cowan, Renee A.
    Afonso, Anoushka M.
    Zhou, Qin
    Iasonos, Alexia
    Ali, Narisha
    Thompson, Errika
    Sonoda, Yukio
    O'Cearbhaill, Roisin E.
    Chi, Dennis S.
    Abu-Rustum, Nadeem R.
    Roche, Kara Long
    GYNECOLOGIC ONCOLOGY, 2018, 151 (02) : 287 - 293
  • [40] Clinical Outcome of Iranian Patients with Advanced Ovarian Cancer with Neoadjuvant Chemotherapy versus Primary Debulking Surgery
    Ghaemmaghami, Fatemeh
    Karimi-Zarchi, Mojgan
    Modares-Gilani, Mitra
    Mousavi, Azamsadat
    Behtash, Nadereh
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2008, 9 (04) : 719 - 724